CA
NZ
UK
AU
IND
US
Corcept Therapeutics Incorporated (NASDAQ: CORT)is a commercial-stage biopharmaceutical company headquartered in the United States. It focuses on discovering and developing therapies that modulate the effects of cortisol to treat a variety of serious disorders in endocrinology, oncology, metabolism, and neurology.
On June 4, 2025, HC Wainwright & Co. upgraded its rating for Agenus (NasdaqCM: AGEN) fromNeutraltoBuy, reflecting a change in analyst sentiment. The firm’s updated outlook comes as the average one-year price target for the clinical-stage immuno-oncology company rises to USD 6.46 per share, …
On June 4, 2025, HC Wainwright & Co. upgraded AnaptysBio (NasdaqGS:ANAB) fromNeutraltoBuy, signaling a shift in sentiment around the biotechnology company. The change follows updated analyst projections that suggest a significant upside potential based on the current share price.
Index Update:U.S. stocks extended gains on Tuesday, with the S&P 500, Nasdaq, and Dow all rising, led by strength in technology shares. Nvidia surged 2.8%, reclaiming its spot as the world’s most valuable publicly traded company. After hours, Hewlett Packard rallied on strong earnings, …
Post Holdings, Inc. (NYSE:POST), consumer-packaged goods holding company, announced that it has entered into a definitive agreement to acquire 8th Avenue Food & Provisions, Inc. (“8th Avenue”) for a net payment of approximately USD 880 million. The transaction includes extinguishing the outstanding net debt …
Gallagher Insurance (NYSE:AJG), a global leader in insurance brokerage, risk management, and consulting services, has entered a multi-year partnership with New Zealand Rugby (NZR), becoming the Official Insurance Broker of the national rugby organization. The announcement was made during a special launch event at …
Redburn Atlantic revised its stance onAdvance Auto Parts (NYSE:AAP)fromSelltoNeutralon June 3, 2025, according to Fintel. This update comes as analysts continue to weigh future expectations for the automotive parts retailer, which has faced mixed performance trends in recent quarters.
On Tuesday,Morgan Stanley (NYSE:MS)upgradedKymera Therapeutics (NASDAQ:KYMR)fromEqualweighttoOverweight, raising its price target toUSD79fromUSD49. The move reflects growing interest in the clinical progress of Kymera's drug pipeline, particularly its STAT6-targeting therapy KT-621.
Index Update:U.S. stocks posted modest gains Monday despite escalating trade tensions between the U.S. and China. The S&P 500, Nasdaq, and Dow all rose, as investors looked ahead to a potential call between Presidents Trump and Xi for clarity on trade. Meanwhile, the EU …
Braze Inc. (Nasdaq: BRZE), a customer engagement technology provider, announced the completion of its acquisition of OfferFit, an AI decisioning company. This follows several years of collaboration between the two firms and aims to integrate OfferFit’s multi-agent decisioning engine into Braze’s Customer Engagement Platform.
Please wait processing your request...